When Is the Evidence Enough? Probability, Risk, and Regulatory Decisions

Regulatory approvals, safety evaluations, quality acceptance criteria, and compliance determinations are fundamentally probabilistic decisions. Yet many professionals rely on statistical results—such as p-values and confidence intervals—without fully understanding how regulators interpret them. Misinterpreting statistical evidence can lead to flawed submissions, weak justifications, or preventable compliance risk.

This webinar explains how probability, uncertainty, and risk thresholds influence regulatory decision-making across clinical, safety, and quality domains. Participants will learn how regulators evaluate evidence, how statistical significance differs from regulatory significance, and how to critically assess the strength of data presented in submissions and audits. Attendees will leave with practical tools to interpret statistical evidence confidently and defensibly.

Why Should You Attend:

Regulatory agencies do not approve products based on “perfect” data — they approve based on whether the evidence is sufficient under uncertainty. Misunderstanding probability concepts can result in weak benefit–risk justifications, overreliance on p-values, or failure to recognize when data lack adequate precision.

FDA and global regulators increasingly scrutinize statistical justification in submissions, non-inferiority margins, safety signals, and quality specifications. Many warning letters and review delays stem not from lack of data, but from misinterpretation or inadequate explanation of uncertainty.

• Do you know how to determine whether your confidence interval truly supports your claim?
• Can you explain the regulatory implications of a borderline p-value?
• Are you confident your team understands the difference between statistical significance and regulatory sufficiency?

This session helps QA and RA professionals avoid costly misinterpretations and strengthen the defensibility of their submissions and compliance decisions.

Areas Covered in the Webinar:

• How probability underpins regulatory approval and compliance decisions
• Understanding uncertainty in regulatory submissions
• What a 95% confidence interval really means in practice
• Type I and Type II error in regulatory and quality contexts
• Statistical significance vs regulatory significance
• Risk tolerance and decision thresholds in different regulatory scenarios
• Precision, sample size, and adequacy of evidence
• Weight of evidence and benefit–risk interpretation
• Common misinterpretations of statistical outputs in submissions
• Practical questions QA/RA leaders should ask when reviewing statistical results

Who Will Benefit:

• Regulatory Affairs Directors and Managers
• Quality Assurance Directors and Managers
• Compliance Officers
• Clinical Quality Professionals
• Medical Affairs Leaders
• CMC Regulatory Managers
• Manufacturing Quality Managers
• Validation and Risk Management Professionals
• Pharmacovigilance Managers
• Regulatory Submission Specialists

Elaine Eisenbeisz
Owner, Omega Statistics

Elaine Eisenbeisz is a Statistician with over 30 years of experience in pharmaceutical and biotechnology research and development. She is the founder of Omega Statistics (est. 2006), a consulting practice guided by the principle of “Elegant Solutions, Effectively Applied.”

Elaine has directed the statistical planning, analytical execution, and regulatory reporting for clinical trials and research, pharmacovigilance activities, real-world evidence studies, and quality systems operating within complex regulatory environments aligned with ICH and FDA guidance. Her work focuses on bridging statistical methodology and regulatory judgment — ensuring that uncertainty, risk tolerance, and evidentiary standards are clearly understood and defensibly applied. She is a recognized educator and advisor who equips QA and Regulatory leaders to interpret statistical evidence with clarity, rigor, and strategic insight.

Follow us :